Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses

Carcinogenesis

Volumn 33, Issue 2, 2012, Pages 436-441

  Kishida, Yugo ^a   Natsume, Atsushi ^a   Kondo, Yutaka ^b   Takeuchi, Ichiro ^c   An, Byonggu ^b   Okamoto, Yasuyuki ^b   Shinjo, Keiko ^b,d   Saito, Kiyoshi ^e   Ando, Hitoshi ^a,e   Ohka, Fumiharu ^a   Sekido, Yoshitaka ^b,d   Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HOX PROTEIN; HOXA6 PROTEIN; PENK PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; TRANSCRIPTION FACTOR HOXA9; TUMOR PROTEIN; UNCLASSIFIED DRUG; UPK3A PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA MICROARRAY; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; MENINGIOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SCORING SYSTEM; TUMOR CLASSIFICATION; TUMOR RECURRENCE;

EID: 84856584735     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr260     Document Type: Article

References (42)

1. Maier, H. et al. (1992) Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J. Neurosurg., 77, 616-623.
2. Perry, A. et al. (1997) Meningioma grading: an analysis of histologic parameters. Am. J. Surg. Pathol., 21, 1455-1465.
3. Aghi, M.K. et al. (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery, 64, 56-60; discussion 60.
4. Perry, A. et al. (1999) "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer, 85, 2046-2056.
5. Willis, J. et al. (2005) The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol. Appl. Neurobiol., 31, 141-149.
6. Al-Mefty, O. et al. (2004) Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J. Neurosurg., 101, 210-218.
7. Hancq, S. et al. (2004) S100A5: a marker of recurrence in WHO grade I meningiomas. Neuropathol. Appl. Neurobiol., 30, 178-187.
8. Lusis, E.A. et al. (2005) Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res., 65, 7121-7126.
9. Surace, E.I. et al. (2004) Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. J. Neuropathol. Exp. Neurol., 63, 1015-1027.
10. Nunes, F. et al. (2005) Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet. Cytogenet., 162, 135-139.
11. Jones, P.A. et al. (2007) The epigenomics of cancer. Cell, 128, 683-692.
12. Barski, D. et al. (2010) Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol., 20, 623-631.
13. McShane, L.M. et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer, 93, 387-391.
14. Toyota, M. et al. (1999) Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res., 59, 2307-2312.
15. Colella, S. et al. (2003) Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques, 35, 146-150.
16. Gao, W. et al. (2008) Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis, 29, 1901-1910.
17. Goto, Y. et al. (2009) Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res., 69, 9073-9082.
18. Okamoto, Y. et al. (2011) Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut. Epub ahead of print. doi:10.1136/gut.2011.241034.
19. Verhaak, R.G. et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110.
20. Monti, S. et al. (2003) Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn., 52, 91-118.
21. Shen, L. et al. (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst., 97, 1330-1338.
22. Shen, L. et al. (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA, 104, 18654-18659.
23. Zhang, X. et al. (2010) Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res., 70, 2350-2358.
24. Nakane, Y. et al. (2007) Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J. Neurosurg., 107, 398-404.
25. Kandenwein, J.A. et al. (2011) uPA/PAI-1 expression and uPA promoter methylation in meningiomas. J. Neurooncol., 103, 533-539.
26. Toyota, M. et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA, 96, 8681-8686.
27. Toyota, M. et al. (1999) Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res., 59, 5438-5442.
28. Noushmehr, H. et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell, 17, 510-522.
29. Morgan, R. (2006) Hox genes: a continuation of embryonic patterning? Trends Genet., 22, 67-69.
30. Lee, T.I. et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell, 125, 301-313.
31. Soshnikova, N. et al. (2008) Epigenetic regulation of Hox gene activation: the waltz of methyls. Bioessays, 30, 199-202.
32. Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin. Cancer Res., 13, 5048-5055.
33. Wu, Q. et al. (2007) DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol. Cancer, 6, 45.
34. Rauch, T. et al. (2007) Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc. Natl Acad. Sci. USA, 104, 5527-5532.
35. Enjuanes, A. et al. (2011) Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. PLoS One, 6, e19736.
36. Ueki, T. et al. (2001) Identification and characterization of differentiallymethylated CpG islands in pancreatic carcinoma. Cancer Res., 61, 8540-8546.
37. Chung, W. et al. (2011) Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol. Biomarkers Prev., 20, 1483-1491.
38. Chung, J.H. et al. (2011) DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch., 459, 201-211.
39. Ju, H.X. et al. (2011) Distinct profiles of epigenetic evolution between colorectal cancers with and withoutmetastasis.Am. J. Pathol., 178, 1835-1846.
40. Ioannidis, P. et al. (2005) CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells. J. Biol. Chem., 280, 20086-20093.
41. Liao, B. et al. (2004) Targeted knockdown of the RNA-binding protein CRD-BP promotes cell proliferation via an insulin-like growth factor IIdependent pathway in human K562 leukemia cells. J. Biol. Chem., 279, 48716-48724.
42. Gu, W. et al. (2009) Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells. J. Cell Sci., 122, 1895-1905.